Adaptive Biotechnologies Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 37.92 million compared to USD 47.83 million a year ago. Net loss was USD 50.3 million compared to USD 45.28 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.32 a year ago.
For the nine months, sales was USD 124.49 million compared to USD 130.11 million a year ago. Net loss was USD 155.81 million compared to USD 160.06 million a year ago. Basic loss per share from continuing operations was USD 1.08 compared to USD 1.12 a year ago.